753 results on '"Jäger, U."'
Search Results
2. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas
3. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
4. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition
5. Imatinib‐induced complete and long‐term sustained remission in chemotherapy‐resistant systemic ALK‐positive anaplastic large cell lymphoma
6. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0
7. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group
8. Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group
9. A Comprehensive Analysis of the Cellular and EBV-Specific MicroRNAome in Primary CNS PTLD Identifies Different Patterns Among EBV-Associated Tumors
10. Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma
11. Tumoren bei immunsupprimierten Patienten
12. Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia
13. Molecular classification of tumour cells in a patient with intravascular large B‐cell lymphoma
14. Lymphoplasmozytisches Lymphom/Makroglobulinämie Waldenström
15. Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis
16. PB2115: TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
17. S212: PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY MANUFACTURED USING T-CHARGE™, IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
18. P1533: TRIAL IN PROGRESS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PARSACLISIB IN PATIENTS WITH PRIMARY WARM AUTOIMMUNE HEMOLYTIC ANEMIA
19. S286: LONG-TERM EFFICACY AND SAFETY RESULTS FROM AN ONGOING OPEN-LABEL PHASE 2 STUDY OF PARSACLISIB FOR THE TREATMENT OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)
20. Tumoren bei immunsupprimierten Patienten
21. Infusional CDE with Rituximab for the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin’s Lymphoma: Preliminary Results of a Phase I/II Study
22. Management of adults and children receiving CAR T- cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
23. Challenge of design for the Westerschelde tunnel in the Netherlands
24. Sensitization of Human Cells to Lysis by Human Complement as an Approach for Cancer Gene Therapy
25. Characterization of height-selective emitters
26. R-metHuG-CSF Combined with Chemotherapy for Treatment of Adult ALL — Pilot Study
27. Impedance platelet aggregometry for surveillance of ibrutinib therapy in chronic lymphocytic leukaemia: 151
28. Echtzeitbildverarbeitung mit Fuzzy Logic
29. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)
30. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
31. Körperhöhe, Körpergewicht und Body Mass Index bei deutschen Wehrpflichtigen. Historischer Rückblick und aktueller Stand
32. 12 th Congress of the European Anthropological Association, 8.-11. September 2000 in Cambridge, England
33. Ergebnisse der Untersuchung ausgewählter Kopfmaße bei Jenaer Kindern
34. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
35. Werden Kopfmaße von Umweltfaktoren beeinflußt?
36. THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION
37. Säkularer Trend bei der Körperhöhe seit dem Neolithikum
38. In memoriam: Herbert Bach 14.3.1926-12.7.1996
39. Bericht über die gemeinsame Tagung des „Fachausschusses T 5.4 Anthropotechnik Lilienthal Oberth e.V.(DGLR)“ und der Arbeitsgemeinschaft „Angewandte Anthropometrie“
40. Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia
41. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma
42. Waldenströmʼs macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
43. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
44. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
45. Cold Agglutinin Disease (CAD) Real World Evidence (CADENCE) registry : Design of the first international, prospective CAD registry
46. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression
47. Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
48. Remission of pure red cell aplasia in T-cell receptor γδ-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab
49. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia
50. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.